ERBITUX®

Merck’s Erbitux BRAF V600E mCRC Regimen Gets EU Approval for First-Line Treatment

By Regulatory Intelligence Desk
15 July 2026

The European Commission has approved Merck’s Erbitux BRAF V600E mCRC combination regimen cetuximab plus encorafenib and FOLFOX as first-line therapy for metastatic colorectal cancer with the BRAF V600E mutation, based on Phase 3 BREAKWATER data showing a 51% reduction in risk of death versus standard chemotherapy.

Clinical Trials News Oncology

Pfizer’s BRAFTOVI Regimen Demonstrates Significant Progression-Free Survival Benefit in Advanced Colorectal Cancer

By Clinical Trials & Data Desk
18 February 2026

Pfizer announced positive progression-free survival results from BREAKWATER trial Cohort 3, showing BRAFTOVI combined with cetuximab and FOLFIRI achieves statistically significant and clinically meaningful progression-free survival improvement compared to chemotherapy alone in previously untreated BRAF V600E-mutant metastatic colorectal cancer patients.

Tag: ERBITUX®

Merck’s Erbitux BRAF V600E mCRC Regimen Gets EU Approval for First-Line Treatment

Pfizer’s BRAFTOVI Regimen Demonstrates Significant Progression-Free Survival Benefit in Advanced Colorectal Cancer

Areas Covered

Discover More

Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN

LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C

GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline

Johnson & Johnson Q2 2026 Analysis: Company Reports $25.3 Billion in Sales, Raises Full-Year Outlook

Merck’s Erbitux BRAF V600E mCRC Regimen Gets EU Approval for First-Line Treatment

AstraZeneca Zegfrovy Deal: AstraZeneca Licenses Dizal’s Oral EGFR Inhibitor for Lung Cancer in Up to $1.5 Billion Agreement